Discovery of a series of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion

ACS Medicinal Chemistry Letters

Volumn 4, Issue 2, 2013, Pages 191-196

  Zheng, Shilong ^a   Zhong, Qiu ^a   Jiang, Quan ^a   Mottamal, Madhusoodanan ^a   Zhang, Qiang ^a   Zhu, Naijue ^a   Burow, Matthew E ^b   Worthylake, Rebecca A ^c   Wang, Guangdi ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anti invasion; antimigration; f actin; fascin; synthesis; thiazole derivatives

Indexed keywords

ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; F ACTIN; FASCIN; THIAZOLE DERIVATIVE;

ACTIN FILAMENT; ALKYLATION; ARTICLE; BREAST CANCER; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; CYCLIZATION; CYTOTOXICITY; DRUG DEVELOPMENT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; METASTASIS; MICROSCOPY; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

EID: 84873961194     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300322n     Document Type: Article

References (34)

1. Chambers, A. F.; Groom, A. C.; MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites Nature Rev. Cancer 2002, 2, 563-572
2. Fidler, I. J. The pathogenesis of cancer metastasis: The "seed and soil" hypothesis revisited Nature Rev. Cancer 2003, 3, 453-458
3. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: The next generation Cell 2011, 144, 646-674
4. Weiss, L. Metastasis of cancer: A conceptual history from antiquity to the 1990s Cancer Metastasis Rev. 2000, 19, 193-383
5. D'Alise, A. M.; Amabile, G.; Iovino, M.; Di Giorgio, F. P.; Bartiromo, M.; Sessa, F.; Villa, F.; Musacchio, A.; Cortese, R. Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells Mol. Cancer Ther. 2008, 7, 1140-1149
6. Watanabe, K.; Ueno, M.; Kamiya, D.; Nishiyama, A.; Matsumura, M.; Wataya, T.; Takahashi, J. B.; Nishikawa, S.; Nishikawa, S.; Muguruma, K.; Sasai, Y. A ROCK inhibitor permits survival of dissociated human embryonic stem cells Nat. Biotechnol. 2007, 25, 681-686
7. Singh, R. P.; Raina, K.; Sharma, G.; Agarwal, R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice Clin. Cancer Res. 2008, 14, 7773-7780
8. Chambers, A. F.; MacDonald, I. C.; Schmidt, E. E; Morris, V. L.; Groom, A. C. Clinical targets for anti-metastasis therapy Adv. Cancer Res. 2000, 79, 91-121
9. Epstein, R. J. Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment Clin. Cancer Res. 2005, 11, 5337-5341
10. Overall, C. M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era Nature Rev. Cancer 2002, 2, 657-672
11. Shi, Z.-G.; Li, J.-P.; Shi, L.-L.; Li, X. An updated patent therapeutic agents targeting MMPs Recent Pat. Anticancer Drug Discovery 2012, 7, 74-101
12. Hua, H.; Li, M.; Luo, T.; Yin, Y.; Jiang, Y. Matrix metalloproteinases in tumorigenesis: An evolving paradigm Cell. Mol. Life Sci. 2011, 68, 3853-3868
13. Rucci, N.; Sanità, P.; Angelucci, A. Roles of metalloproteases in metastatic niche Curr. Mol. Med. 2011, 11, 609-622
14. Raffo, D.; Pontiggia, O. Simian, M. Role of MMPs in metastatic dissemination: Implications for therapeutic advances Curr. Pharm. Biotechnol. 2011, 12, 1937-1947
15. Dormán, G.; Cseh, S.; Hajdú, I.; Barna, L.; Kónya, D.; Kupai, K.; Kovács, L.; Ferdinandy, P. Matrix metalloproteinase inhibitors: A critical appraisal of design principles and proposed therapeutic utility Drugs 2010, 70, 949-964
16. Fingleton, B. MMPs as therapeutic targets-Still a viable option? Semin. Cell Dev. Biol. 2008, 19, 61-68
17. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs Nat. Rev. Cancer 2004, 4, 253-265
18. Qiu, X.-L.; Li, G.; Wu, G.; Zhu, J.; Zhou, L.; Chen, P.-L.; Chamberlin, A. R.; Lee, W.-H. Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues J. Med. Chem. 2009, 52, 1757-1767
19. Hollebecque, A.; Massard, C.; Soria, J. C. Vascular disrupting agents: A delicate balance between efficacy and side effects Curr. Opin. Oncol. 2012, 24, 305-315
20. Spear, M. A.; LoRusso, P.; Mita, A.; Mita, M. Vascular disrupting agents (VDA) in oncology: Advancing towards new therapeutic paradigms in the clinic Curr. Drug Targets 2011, 12, 2009-2015
21. Marrelli, M.; Conforti, F.; Statti, G. A.; Cachet, X.; Michel, S.; Tillequin, F.; Menichini, F. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin A-4 Curr. Med. Chem. 2011, 18, 3035-3081
22. Heath, V. L.; Bicknell, R. Anticancer strategies involving the vasculature Nat. Rev. Clin. Oncol. 2009, 6, 395-404
23. Schwartz, E. L. Antivascular actions of microtubule-binding drugs Clin. Cancer Res. 2009, 15, 2594-2601
24. Romagnoli, R.; Baraldi, P. G.; Brancale, A.; Ricci, A.; Hamel, E.; Bortolozzi, R.; Basso, G.; Viola, G. Convergent synthesis and biological evaluation of 2-amino-4-(3′,4′,5′-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents J. Med. Chem. 2011, 54, 5144-5153
25. Kennedy, A. J.; Mathews, T. P.; Kharel, Y.; Field, S. D.; Moyer, M. L.; East, J. E.; Houck, J. D.; Lynch, K. R.; Macdonald, T. L. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells J. Med. Chem. 2011, 54, 3524-3548
26. Romagnoli, R.; Baraldi, P. G.; Salvador, M. K.; Preti, D.; Aghazadeh Tabrizi, M.; Brancale, A.; Fu, X. H.; Li, J.; Zhang, S. Z.; Hamel, E.; Bortolozzi, R.; PorcuÌ€, E.; Basso, G.; Viola, G. Discovery and optimization of a series of 2-aryl-4-amino-5-(3′,4′,5′- trimethoxybenzoyl)thiazoles as novel anticancer agents J. Med. Chem. 2012, 55, 5433-5445
27. Cushing, T. D.; Metz, D. P.; Whittington, D. A.; McGee, L. R. PI3Kδ and PI3Kγ as Targets for Autoimmune and inflammatory diseases J. Med. Chem. 2012, 55, 8559-8581
28. Li, W. W.; Wang, X. Y.; Zheng, R. L.; Yan, H. X.; Cao, Z. X.; Zhong, L.; Wang, Z. R.; Ji, P.; Yang, L. L.; Wang, L. J.; Xu, Y.; Liu, J. J.; Yang, J.; Zhang, C. H.; Ma, S.; Feng, S.; Sun, Q. Z.; Wei, Y. Q.; Yang, S. Y. Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy) quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo J. Med. Chem. 2012, 55, 3852-3866
29. Schade, A. E.; Schieven, G. L.; Townsend, R.; Jankowska, A. M.; Susulic, V.; Zhang, R.; Szpurka, H.; Maciejewski, J. P. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation Blood. 2008, 111, 1366-1377
30. Sharma, S.; Saha, B.; Sawant, D.; Kundu, B. Synthesis of Novel N-Rich Polycyclic Skeletons Based on Azoles and Pyridines J. Comb. Chem. 2007, 9, 783-792
31. Chen, L.; Yang, S.; Jakoncic, J.; Zhang, J. J.; Huang, X. Y. Migrastatin analogues target fascin to block tumour metastasis Nature 2010, 464, 1062-1066
32. Erratum in: Nature 2011, 476, 240.
33. Hashimoto, Y.; Kim, D. J.; Adams, J. C. The roles of fascins in health and disease J. Pathol. 2011, 224, 289-300
34. Jayo, A.; Parsons, M. Fascin: A key regulator of cytoskeletal dynamics Int. J. Biochem. Cell Biol. 2010, 42, 1614-1617